This clinical trial is focused on studying the effects of the medication Digoxin in treating patients with Heart Failure. Heart failure is a condition where the heart is unable to pump blood effectively, leading to symptoms like shortness of breath and fatigue. The study aims to assess how well Digoxin works when combined with modern heart failure treatments, which typically include medications like ARNi, ACE inhibitors, beta-blockers, SGLT2 inhibitors, and MRAs.

Participants in the study will receive either Digoxin or a placebo, and their progress will be monitored over a period of 24 weeks. During this time, researchers will evaluate the participants’ heart function and overall physical capacity. This will involve tests such as measuring peak oxygen consumption and using echocardiography, which is an ultrasound of the heart, to assess how well the heart is working.

The study will also look at other health outcomes, such as the occurrence of hospitalizations, changes in certain blood markers, and overall quality of life. By the end of the study, the researchers hope to better understand the role of Digoxin in managing heart failure and improving patients’ health and well-being.